Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Glatting

Showing results (81-90 of 150) with videos related to

Pageof 15
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 25, 2003
A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapyInga Buchmann, Thomas Kull, Gerhard Glatting, et al.
Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003
F-18 Fluorodeoxyglucose (FDG) and C-Reactive Protein (CRP)Christoph G. Diederichs, Ludger Staib, Bernhard Glasbrenner, et al.
Medical Physics|September 11, 2012
Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapyPeter Kletting, Berthold Muller, Bahar Erentok, et al.
Plos One|November 5, 2014
Quantitative and qualitative assessment of Yttrium-90 PET/CT imagingAli Asgar Attarwala, Flavia Molina-Duran, Karen-Anett Büsing, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 16, 2018
EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculationsJonathan I Gear, Maurice G Cox, Johan Gustafsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2018
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for <sup>177</sup>Lu-Labeled PSMA PeptidesNusrat J Begum, Anne Thieme, Nina Eberhardt, et al.
Radiology|December 21, 2006
Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial ExperienceAnja Dankerl, Peter Liebisch, Gerhard Glatting, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 25, 2025
A mathematical model for the investigation of combined treatment of radiopharmaceutical therapy and PARP inhibitorsMarc Ryhiner, Yangmeihui Song, Jimin Hong, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|December 4, 2024
Few-time-points time-integrated activity coefficients calculation using non-linear mixed-effects modeling: Proof of concept for [<sup>111</sup>In]In-DOTA-TATE in kidneysRizky Mahardhika Subangun, Deni Hardiansyah, Raushan Fikr Ilham Ibrahim, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 25, 2002
FDG uptake in breast cancer: correlation with biological and clinical prognostic parametersAndreas Buck, Holger Schirrmeister, Thorsten Kühn, et al.
Pageof 15

Showing results (81-90 of 150) with videos related to

Sort By:
Pageof 15
European Journal of Nuclear Medicine and Molecular Imaging|February 25, 2003
A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapyInga Buchmann, Thomas Kull, Gerhard Glatting, et al.
Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003
F-18 Fluorodeoxyglucose (FDG) and C-Reactive Protein (CRP)Christoph G. Diederichs, Ludger Staib, Bernhard Glasbrenner, et al.
Medical Physics|September 11, 2012
Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapyPeter Kletting, Berthold Muller, Bahar Erentok, et al.
Plos One|November 5, 2014
Quantitative and qualitative assessment of Yttrium-90 PET/CT imagingAli Asgar Attarwala, Flavia Molina-Duran, Karen-Anett Büsing, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 16, 2018
EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculationsJonathan I Gear, Maurice G Cox, Johan Gustafsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2018
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for <sup>177</sup>Lu-Labeled PSMA PeptidesNusrat J Begum, Anne Thieme, Nina Eberhardt, et al.
Radiology|December 21, 2006
Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial ExperienceAnja Dankerl, Peter Liebisch, Gerhard Glatting, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 25, 2025
A mathematical model for the investigation of combined treatment of radiopharmaceutical therapy and PARP inhibitorsMarc Ryhiner, Yangmeihui Song, Jimin Hong, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|December 4, 2024
Few-time-points time-integrated activity coefficients calculation using non-linear mixed-effects modeling: Proof of concept for [<sup>111</sup>In]In-DOTA-TATE in kidneysRizky Mahardhika Subangun, Deni Hardiansyah, Raushan Fikr Ilham Ibrahim, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 25, 2002
FDG uptake in breast cancer: correlation with biological and clinical prognostic parametersAndreas Buck, Holger Schirrmeister, Thorsten Kühn, et al.
Pageof 15